Mesoblast Limited (NASDAQ: MESO) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT MESOBLAST LIMITED

Mesoblast Limited (NASDAQ: MESO)
Listen to this Section


$15.46
+0.0200 ( +0.13% ) 0.6K

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.

Clinical Trial Pipeline Stages


Drug Name Stage
RexlemestrocelDetailsChronic lower back pain Phase 3
Remestemcel-LDetailsInflammatory bowel disease, Bowel disorder, Crohns disease Failed
Remestemcel-L (mesenchymal stem cells)DetailsCOVID-19 Failed

Market Data


Open $15.46
Previous Close $15.44
Volume 0.6K
Market Cap $2.00B
Day Range $15.46 - $15.46
52 Week Range $10.96 - $21.50
Shares Outstanding 129.28M
Change % +0.13%
Net Change ▲ 0.0200
Insider Ownership N/A
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
IPO Year2009
CountryAustralia
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: 0.00

Date Type Amount Purchased Purchaser
No records found.

SEC Filings


Form Type Description Pages Date
6-k Form 6-K 5 Nov 05, 2025
6-k Form 6-K 11 Oct 29, 2025
6-k Form 6-K 329 Oct 28, 2025
6-k Form 6-K 11 Oct 22, 2025
6-k Form 6-K 25 Oct 15, 2025
6-k Form 6-K 4 Oct 07, 2025
6-k Form 6-K 4 Oct 03, 2025
6-k Form 6-K 4 Sep 29, 2025
6-k Form 6-K 5 Sep 15, 2025
6-k Form 6-K 4 Sep 15, 2025

Latest News